肾移植中应用更昔洛韦治疗巨细胞病毒性肺炎
Treatment of cytomegalovirus pneumonitis with ganciclovir in renal transplantation.
作者信息
Stoffel M, Pirson Y, Squifflet J P, Lamy M, Gianello P, Alexandre G P
机构信息
Department of Renal Transplantation, University of Louvain Medical School, Cliniques U.C.L. Saint-Luc, Brussels, Belgium.
出版信息
Transpl Int. 1988 Dec;1(4):181-5. doi: 10.1111/j.1432-2277.1988.tb01812.x.
Ganciclovir, also called DHPG, was administered intravenously to eight renal transplant recipients with life-threatening cytomegalovirus (CMV) pneumonitis. One patient died of pulmonary failure; a favorable clinical response was observed in the seven others. In one patient, CMV pneumonitis recurred but responded well to a second course of the drug. At no time was the immunosuppressive regimen completely stopped in the seven surviving patients. Six of them maintained a good renal function 1-11 months after treatment with ganciclovir. No toxic effect was detected during therapy. We conclude that ganciclovir appears to be a promising and effective treatment for CMV pneumonitis after renal transplantation.
更昔洛韦，也称为DHPG，被静脉注射给8名患有危及生命的巨细胞病毒（CMV）肺炎的肾移植受者。1名患者死于呼吸衰竭；其他7名患者观察到良好的临床反应。1名患者的CMV肺炎复发，但对第二个疗程的药物反应良好。在7名存活患者中，免疫抑制方案从未完全停止。其中6名患者在接受更昔洛韦治疗后1至11个月保持良好的肾功能。治疗期间未检测到毒性作用。我们得出结论，更昔洛韦似乎是肾移植后CMV肺炎一种有前景且有效的治疗方法。
Zotero 插件